SCHEMBL6090378

SCHEMBL6090378

O=C1CCN2c3c1cccc3C(=O)NC2c1ccsc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.36
KMT2A Q03164 2/20 0.36
HSD17B10 Q99714 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTR2C P28335 2/20 0.35
HTR2B P41595 2/20 0.35
CYP19A1 P11511 1/20 0.34
LMNA P02545 2/20 0.33
SLC22A12 Q96S37 2/20 0.33
AKT1 P31749 1/20 0.33
HTT P42858 2/20 0.32
POLB P06746 2/20 0.32
USP2 O75604 1/20 0.32
NSD2 O96028 1/20 0.32
CASP1 P29466 1/20 0.32
BRCA1 P38398 1/20 0.32
CASP7 P55210 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6090523 0.84 TNKS2 (0.39) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6091873 0.81 MEN1 (0.42) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6089877 0.81 PARP1 (0.39) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6089480 0.81 TNKS2 (0.42) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6091087 0.80 SMN1; SMN2 (0.33) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6089450 0.80 SMN1; SMN2 (0.33) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6091674 0.80 SMN1; SMN2 (0.33) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6090517 0.80 SMN1; SMN2 (0.33) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6090229 0.78 ALDH1A1 (0.41) KDM4EMEN1MAPTKMT2AHSD17B10
SCHEMBL6090894 0.78 ATM (0.41) KDM4EMEN1MAPTKMT2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004028-A1 Novel PARP inhibitor MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1582520-A1 NOVEL PARP INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2005-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004028-A1 Novel PARP inhibitor PARP1, PARP2, PARP11 KDM4E 812/4885MEN1 2771/4885MAPT 497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.